Sirolimus- vs. paclitaxel-eluting balloons for the treatment of coronary in-stent restenosis: a systematic review and meta-analysis

European Heart Journal Supplements

16 November 2026
Organised by: Logo
ESC Journals

Abstract

AbstractBackground

In-stent restenosis (ISR) remains a major limitation of percutaneous coronary intervention (PCI), even in the drug-eluting stent era. Drug-eluting balloons (DEB) have emerged as an alternative to repeat stenting by providing homogeneous antiproliferative drug delivery without additional metal layers. Recent generations of sirolimus-coated balloons (SCB) may offer improved outcomes compared to paclitaxel-coated balloons (PCB).

Methods

A systematic search was conducted in PubMed, Embase, and Scopus databases for studies published between January 2020 and October 2025 comparing SCB and PCB in the treatment of ISR. Primary endpoints included late lumen loss (LLL) and binary restenosis. Secondary endpoints were target lesion revascularization (TLR) and major adverse cardiac events (MACE). Data extraction and quality assessment followed PRISMA guidelines, and pooled analysis was performed using a random-effects model.

Results

Eleven studies with a total of 3240 patients met inclusion criteria. SCB demonstrated significantly lower LLL (mean difference −0.11 mm; P = 0.02) and a trend toward reduced TLR (OR 0.78; 95% CI 0.59–1.02). No significant difference was observed in MACE or mortality between groups. Study heterogeneity was low for most endpoints (I2 < 35%).

Conclusions

Sirolimus-coated balloons appear to provide superior angiographic outcomes and comparable safety compared to paclitaxel-coated balloons in ISR management. Further large-scale randomized trials with long-term follow-up are warranted to confirm these findings.

Contributors